2017
DOI: 10.7175/fe.v18i1.1324
|View full text |Cite
|
Sign up to set email alerts
|

Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

Abstract: BACKGROUND: Inflammatory bowel disease (IBD) represents a group of chronic conditions characterized by elevated costs. Over the last years, also a considerable healthcare burden associated with IBD has emerged, due to an increasing use of biological drugs and hospitalization costs. Despite the creation of local or regional databases, data regarding healthcare expenditure are lacking in Italy. AIM: To evaluate the treatment cost (biological drugs and hospitalizations) for patients with ulcerative colitis (UC) o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
3
0
2

Year Published

2018
2018
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 14 publications
0
3
0
2
Order By: Relevance
“…Uno studio osservazionale retrospettivo è stato condotto in Italia per i pazienti con UC e con MC, limitatamente a un centro del Nord-Est del paese 18 durante il periodo maggio 2015-aprile 2016. Il costo medio mensile per i pazienti con UC ammontava a €1.235, mentre per i pazienti con CD ammontava a €1.148.…”
Section: Discussioneunclassified
“…Uno studio osservazionale retrospettivo è stato condotto in Italia per i pazienti con UC e con MC, limitatamente a un centro del Nord-Est del paese 18 durante il periodo maggio 2015-aprile 2016. Il costo medio mensile per i pazienti con UC ammontava a €1.235, mentre per i pazienti con CD ammontava a €1.148.…”
Section: Discussioneunclassified
“…Per i 477 pazienti trattati con infliximab, analizzando il totale CU più MC, si rileva che solamente due variabili spiegano le differenze di costo fra pazienti, sebbene debolmente (R2 = 0,211091) e sono: la durata della malattia e il numero di comorbidità ( Tabella 3) A differenza dei pazienti trattati con infliximab, quelli trattati con adalimumab per entrambe CU e MC trovano Uno studio osservazionale retrospettivo è stato condotto in Italia per i pazienti con UC e con MC, limitatamente a un centro del Nord-Est del paese 18 durante il periodo maggio 2015-aprile 2016. Il costo medio mensile per i pazienti con UC ammontava a €1.235, mentre per i pazienti con CD ammontava a €1.148.…”
Section: Analisi Multivariataunclassified
“…IBD mainly affects young people, of both genders, with comparable incidence (age range 15–40 years) [ 2 , 3 ]. Being a chronic disease, IBD generates a significant reduction in the quality of life [ 4 ] and high consumption of healthcare resources (medications, outpatient visits, hospitalizations, and surgeries) [ 5 ]. IBD is characterized by chronic inflammation of the bowel and by several extra-intestinal manifestations which are present in 25–40% of IBD patients [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…The pathogenetic explanation of IDA in IBD patients could be related to several factors, which result from chronic blood loss and/or reduced iron absorption and reduced iron intake [ 9 ]. IDA subsequent to IBD is associated with reduced quality of life, an increase in work absenteeism, an increased frequency of hospitalization, and increased healthcare costs [ 4 , 5 ]. Thus, there is a clear need to support IDA patients with pharmacological treatments, to improve their quality of life and physical condition, and alleviate fatigue and cognitive deficits [ 10 ].…”
Section: Introductionmentioning
confidence: 99%